ACIU - AC Immune SA
| Previous Close | 5.14 |
| Open | 5.18 |
| Bid | 5.35 x 1000 |
| Ask | 7.00 x 1800 |
| Day's Range | 5.10 - 5.45 |
| 52 Week Range | 3.25 - 12.50 |
| Volume | 107,354 |
| Avg. Volume | 105,256 |
| Market Cap | 363.485M |
| Beta (3Y Monthly) | 0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings Date | Nov 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.41 |
- GlobeNewswire
AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update
LAUSANNE, Switzerland, Aug. 14, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative.
- GlobeNewswire
AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases
LAUSANNE, Switzerland, Aug. 12, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- Zacks
Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
AC Immune Initiates Phase I Study for Alzheimer's Disease
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
- GlobeNewswire
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
LAUSANNE, Switzerland, July 17, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a.
- GlobeNewswire
AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced initial interim data from an ongoing Phase 1b trial of the ACI-24 anti-Abeta vaccine to treat Alzheimer’s disease (AD) like symptoms in subjects with Down syndrome (DS) as well as key takeaways from its Key Opinion Leader (KOL) meeting, held in New York City. Professor Andrea Pfeifer, CEO of AC Immune, commented: “These initial interim Phase 1b data support the continued study of ACI-24 in this trial to treat AD-like symptoms in DS as well as in our ongoing Phase 2 trial in subjects with mild AD.
- Simply Wall St.
Introducing AC Immune (NASDAQ:ACIU), The Stock That Slid 66% In The Last Year
AC Immune SA (NASDAQ:ACIU) shareholders should be happy to see the share price up 11% in the last quarter. But that...
- Insider Monkey
Here’s What Hedge Funds Think About AC Immune SA (ACIU)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of March 31. The results of that effort will be put on display in this article, as […]
- GlobeNewswire
AC Immune Announces Election of New Chairman of the Board at Annual General Meeting
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced that shareholders in the Company have elected Douglas Williams as Chairman of the Board at today’s Annual General Meeting (AGM). At the AGM held in Lausanne, shareholders also elected Martin Velasco, previously Chairman, as Vice-Chairman of the Board.
- GlobeNewswire
AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer’s in Down Syndrome
LAUSANNE, Switzerland, June 27, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering.
- GlobeNewswire
AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease
AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, has initiated a substudy in the ongoing Phase 2 Alzheimer’s Prevention Initiative (API) trial of AC Immune’s investigational candidate, crenezumab. The substudy, which measures Tau burden using Positron Emission Tomography (PET), aims to increase the understanding of disease progression in the preclinical stage of autosomal dominantly inherited Alzheimer’s disease (familial AD).
- Zacks
AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
AC Immune: 1Q Earnings Snapshot
The Lausanne, Switzerland-based company said it had net income of 91 cents per share. Earnings, adjusted for non-recurring gains, came to 85 cents per share. The biopharmaceutical company posted revenue ...
- GlobeNewswire
AC Immune Reports Q1 2019 Financial Results and Business Update
LAUSANNE, Switzerland, May 15, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering.
- Zacks
AC Immune (ACIU) to Report Q1 Results: Wall Street Expects Earnings Growth
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
What Percentage Of AC Immune SA (NASDAQ:ACIU) Shares Do Insiders Own?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls AC Immune SA (NASDAQ:ACIU), then you'll have to look at the makeup of its share regis...
- Zacks
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.
- GlobeNewswire
AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference
LAUSANNE, Switzerland, April 01, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- GlobeNewswire
AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference
Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther.
- Zacks
Lilly (LLY) Signs New Immunology Deal With Private Biotech
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
- GlobeNewswire
New Clinical Data on AC Immune’s Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD™ Conference
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP New data further support 18F-PI-2620’s potential as.
- Zacks
What Makes AC Immune (ACIU) a New Buy Stock
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire
AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update
CHF 300 million cash position as of Q1 2019 funds operations through Q3 2023 Eli Lilly deal validates MorphomerTM platform Initiation of second Phase 2 trial of Tau antibody.
- GlobeNewswire
AC Immune to Report Progress of Early-Stage Pipeline at AD/PD™ Congress
LAUSANNE, Switzerland, March 04, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
